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Abstract
Background: It is known that tissue and serum sialic acid levels may be altered by malignant
transformation. In this study, sialic acid levels were determined in bronchoalveolar lavage fluid
(BAL) and serum in two groups of patients with lung cancer and non-malignant diseases of the lung.
Methods: Colorimetric methods were used for determination sialic acid in serum and in BAL
samples. Flexible bronchoscopy was used to obtain the latter.
Results: Sialic acid levels in bronchoalveolar lavage fluid and serum did not show any statistically
significant difference between subjects with malignant and the non-malignant lung diseases (p >
0.05). Sialic acid levels were also unrelated to the stage and localization of the tumor (p > 0.05).
Conclusions: Sialic acid levels do not appear to be a good marker for discriminating malignant
from non-malignant diseases of the lung.
Background
Sialic acid (N-acetylneuraminic acid; NANA) is com-
posed of alkylated derivatives of the neuraminic acid,
which are present in various mucoproteins and as the
carbohydrate component of cell membrane glycolipids.
The carbohydrate moiety characterizes the cohesive, ad-
hesive and antigenic properties by its effect on cell-to-
cell contacts. These properties often change substantially
after malignant transformation of a cell. In addition, de-
velopment of malignancy could affect the serum and tis-
sue sialic acid levels as well [1]. Sialic acid molecules can
potentially inhibit intermolecular and intercellular inter-
actions by virtue of their negative charge. However, they
can also act as critical components of ligands recognized
by a variety of animal, plant, and microbial proteins
termed sialic acid binding lectins [2]. Sialic acid concen-
trations vary physiologically with age, but their levels
may also be influenced by such conditions as inflamma-
tion, neoplastic tumors or inborn genetic disorders,
which cause abnormal sialic acid metabolism [3].
In this study we intended to determine sialic acid levels
in BAL fluid and serum in patients with lung cancer and
non-cancer diseases of the lung and compare the results.
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Methods
A total of 40 patients were enrolled. Mean age was 50.6
(range: 19–75) with the male to female ratio being 20:1.
Twenty-one patients (Group 1) had been diagnosed with
lung cancer (Table 1), and the remaining 19 (Group 2)
had various non-malignant lung diseases consisting of
infections for the most part (Table 2). Informed consent
was obtained from every patient participating the study.
We measured BAL fluid and serum sialic acid levels in
each patient. BAL fluid was obtained in the same manner
in all, utilizing flexible fiberoptic bronchoscopy. The up-
per respiratory tract was anesthetized using 2% lidocaine
and atropine (0.75 mg IM) administered before the pro-
cedure. Two 50-mL aliquots of sterile saline, pre-
warmed to 37°C, were infused into appropriate lung seg-
ments. Fluid was immediately recovered using gentle
suction after introduction of each aliquot. BAL samples
were obtained from the lobe containing the cancer in pa-
tients with lung cancer, from the segment(s) of greatest
involvement in patients with pneumonia and lung tuber-
culosis, and from the right middle lobe in the setting of
other diseases. The recovered fluid was passed through
monolayer surgical gauze to eliminate mucus. Colori-
metric method (Shimadzu UV-1601) was used for detec-
tion of sialic acid (Sigma, A0812, Type IV-S). A 14-fold
concentrate of lavage fluid was used in the measurement
process; appropriate dilution factors were used in subse-
quent calculation of results.
Results
Mean sialic acid levels in BAL fluid of lung cancer pa-
tients were 10.31 ± 6.53 mg/dl and 7.34 ± 3.08 mg/dl in
the non-cancer group. Mean serum sialic acid level in the
former was 81.97 ± 27.80 mg/dl and 72.05 ± 23.18 mg/dl
in the latter group. BAL fluid and serum sialic acid values
of both patient groups are shown in Figure 1. Compari-
son of the values was made with the non-parametric
Mann-Whitney test. BAL fluid sialic acid levels did not
show a statistically significant difference between cancer
and non-cancer groups (p > 0.05). Serum levels also
failed to display any significant difference (p > 0.05) be-
tween the two groups. Moreover there was not a mean-
ingful difference between sialic acid levels from the BAL
fluids and sera of subjects at different stages of lung can-
cer (p > 0.05). Lastly, neither did central or peripheral
localization of the lung cancer confer any significant dif-
ference (p > 0.05).
Discussion
Several studies have been performed about determina-
tion of different tumor markers in the serum and in BAL
for the diagnosis of lung cancer and even for the type of
tumor. Macchia et al (1987) have reported that the simul-
taneous determination of carcinoembryonic antigen
(CEA) and CanAg CA-50 or neuron-specific enolase
(NSE) in serum and in BAL is a useful aid in the diagno-
sis of lung malignancy [4]. To determine the usefulness
of CEA in diagnosing lung cancer not visible endoscopi-
cally, de Diego et al (1991) compared CEA levels in BAL
fluid and serum of patients with lung cancer, pneumo-
nia, and healthy individuals [5]. They suggested that
CEA determination in BAL fluid should not be used as
the only diagnostic procedure. Niklinski et al (1992) de-
clared that the simultaneous determination of CEA and
squamous cell carcinoma antigen levels in serum and
BAL in lung carcinoma patients might be of considerable
importance in diagnosis [6]. To evaluate the diagnostic
usefulness of simultaneous determinations of CEA, NSE,
chorionic gonadotrophin (HCG), and carbohydrate anti-
genic determinant 19–9 (CA 19–9), Niklinski et al (1993)
studied 48 patients with small cell lung carcinoma
(SCLC) and 15 with nonmalignant lung disease [7]. The
combination of CEA and NSE in BAL and NSE in serum
taken together with results of bronchoscopy (histologic
and cytologic) showed the highest discriminating power
between malignant (SCLC) and nonmalignant lung dis-
ease [7].
Neuron-specific enolase is used in the staging and mon-
itoring of responses to therapy and the detection of re-
Figure 1
Sialic acid values in BAL fluid and sera of each patient group.BMC Pulmonary Medicine 2001, 1:4 http://www.biomedcentral.com/1471-2466/1/4
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currences in lung cancer [8]. The diagnostic value of NSE
has been under discussion. Prados et al. (1994) reported
that NSE could be of aid in the early diagnosis of solitary
pulmonary nodules and lung cancer [8]. Dowlati et al
(1996) reported that high levels of NSE have recently
been described in BAL fluid of patients with lung carci-
noma [9]. BAL NSE is a better predictor of malignancy
than serum NSE. BAL fluid measurements of NSE may
have diagnostic value, especially if it is simultaneously
measured in the serum [9].
Dowlati et al (1996) conducted a study to evaluate the
usefulness of gastrin measurements in lung cancer and
COPD patients and they found no difference between the
gastrin levels in the BAL fluid or serum of the study
groups [10]. There was no correlation with the stage in
non-small cell lung carcinoma and no correlation was
found between the gastrin levels in the serum and the
BAL fluid. Therefore they concluded that there was no
evidence of clinical usefulness for gastrin measurements
in lung cancer [10].
Pina et al (2001) aimed to assess the diagnostic yield of
the tumor markers carbohydrate antigen (CA125), CEA,
NSE, squamous cell carcinoma antigen and specific tis-
sue polypeptide antigen (TPS) in serum, BAL and biopsy
cytosol in a group of patients with bronchogenic carcino-
ma [11]. This study suggested that determination of CEA
Table 1: Sialic acid levels in BAL and sera samples of patients with malignant lung diseases (mg/dl).
Patient No. Age BAL Fluid Serum Diagnosis Tumor Localization Tumor Stage
1 55 3.75 64.25 Epidermoid carcinoma Central Stage IIB
2 50 1.87 88.60 Epidermoid carcinoma Central Stage IIIA
3 64 5.97 73.69 Epidermoid carcinoma Central Stage IIIA
4 68 11.09 143.96 Epidermoid carcinoma Peripheral Stage IIIB
5 60 7.39 83.93 Small cell carcinoma Central Stage IV
6 55 7.52 101.74 Epidermoid carcinoma Central Stage IIB
7 72 7.78 134.70 Small cell carcinoma Central Stage IV
8 59 8.8 46.07 Adenocarcinoma Peripheral Stage IIIB
9 61 10.4 73.82 Epidermoid carcinoma Central Stage IB
10 45 2.64 86.26 Adenocarcinoma Peripheral Stage IIB
11 59 11.6 103.24 Epidermoid carcinoma Central Stage IIIA
12 66 4.4 92.14 Epidermoid carcinoma Peripheral Stage IIB
13 62 20 66.61 Epidermoid carcinoma Central Stage IB
14 48 16.4 103.24 Epidermoid carcinoma Central Stage IIIA
15 51 9.2 82.71 Small cell carcinoma Central Stage IV
16 50 11.6 27 Epidermoid carcinoma Central Stage IIIA
17 70 4.4 87.98 Epidermoid carcinoma Peripheral Stage IIB
18 48 17.9 91.86 Adenocarcinoma Peripheral Stage IIIA
19 75 9.2 65.77 Epidermoid carcinoma Central Stage IIIB
20 65 28.8 42.35 Large cell carcinoma Central Stage IIIA
21 68 15.9 61.61 Large cell Carcinoma Central Stage IIIB
Table 2: Sialic acid levels in BAL and sera samples of patients with 
benign lung diseases (mg/dl).
Patient 
No.
Age BAL Fluid Serum Diagnosis
1 60 0.93 98.3 Pneumonia
2 75 8.43 82.9 Pneumonia
3 48 7.96 63.44 Lung abscess
4 3 54 . 9 37 5 L u n g  t u b e r c u l o s i s
5 40 5.6 63 Pneumonia
6 24 9.2 51.90 Lung tuberculosis
7 28 7.6 69.38 Lung tuberculosis
8 49 7.2 91.31 Pneumonia
9 30 11.6 69.11 Sarcoidosis
10 34 2.4 56.34 Lung tuberculosis
11 19 7.6 90.75 Lung tuberculosis
12 60 8.4 72.44 Lung tuberculosis
13 25 7.2 74.66 Pneumonia
14 60 68.55 10.50 COPD
15 43 8.4 57.17 Lung tuberculosis
16 25 5.6 125.17 Lung abscess
17 50 10.4 58.28 Pneumonia
18 28 13.9 70.49 Lung tuberculosis
19 43 3.6 88.81 PneumoniaBMC Pulmonary Medicine 2001, 1:4 http://www.biomedcentral.com/1471-2466/1/4
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in BAL was clinically the most useful marker in compar-
ison with serum and cytosol determinations, although
the latter may also be helpful in certain situations. Al-
though there is no specific tumor marker for lung cancer,
the combination of several can be used to monitor most
patients with lung cancer [11].
Sialic acid levels have also been taken into account as a
marker for lung cancer. Krolikowski et al (1976) showed
that there is a significant difference in the levels of sialic
acid in patients with lung cancer compared to normal
controls. Hence they reported sialic acid to be of value as
a biologic marker in lung cancer [12]. Seber et al (1989)
also showed that sialic acid levels in BAL fluid were high-
ly correlated with the diagnosis of bronchial cancer [13].
Kakari et al (1991) determined total sialic acid (TSA) and
lipid-bound sialic acid (LSA) concentrations in compari-
son to CEA levels in 152 untreated patients with primary
lung cancer and 107 benign pulmonary diseases. They
concluded that although TSA and LSA were highly sensi-
tive markers of lung cancer, their specificity was low in
this setting [14]. Imecik et al (1992) measured sialic acid
levels in the pleural effusions from patients with malig-
nant and benign lung pathologies. Finding higher sialic
acid concentrations in malignant pleural effusions than
in those of benign origin, they concluded that the sialic
acid had diagnostic value [15]. In another study by Patel
et al (1995), carcinoembriyonic antigen (CEA) and phos-
phohexose isomerase (PHI) levels along with total sialic
acid/total protein ratios (TSA/TP) in 192 untreated lung
cancer patients and in 80 age- and sex-matched control
cases were compared. PHI and TSA/TP were found to be
as an important tumor marker in patients with lung can-
cer [16].
We attempted in this study to more precisely define the
potential role of sialic acid as a diagnostic marker in lung
cancer by comparing its levels in malignant and benign
conditions of the lung. However, we were not able to ob-
serve a clinically meaningful difference with respect to
sialic acid concentrations between these two categories.
Conclusions
In this study, comparison of sialic acid levels in either
BAL fluid or serum failed to show any statistically signif-
icant difference between patients with lung cancer and
non-malignant, mostly infectious, pulmonary diseases.
We therefore conclude that determination of sialic acid
in the diagnostic evaluation of lung cancer needs more
extensive study. Patients in remission might require a
more cautious approach in this respect. We also believe
that studies to clarify the exact role of sialic acid levels in
the setting of inflammatory diseases will be useful as
well.
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